HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Rodgers, H.C. Articles by Knox, A.J. Search for Related Content PubMed PubMed Citation Articles by Rodgers, H.C. Articles by Knox, A.J.

Pharmacological treatment of the biochemical defect in cystic fibrosis airways

Respiratory Medicine Unit, City Hospital, Nottingham, UK

CORRESPONDENCE: A.J. Knox, Respiratory Medicine Unit, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. Fax: 44 1158404771

Keywords: amiloride, cystic fibrosis, ion transport, pharmacogenetics, trafficking, treatment

Received: October 2, 2000
Accepted January 10, 2001

This study was supported by the UK Cystic Fibrosis Trust.

Abstract

The understanding of the biochemical defect in cystic fibrosis (CF) has advanced considerably since discovery of the CF gene in 1989 and characterization of its product. Studies showing that the abnormality in chloride flux could be corrected by transfection of wild-type cystic fibrosis transmembrane conductance regulator (CFTR) complimentary deoxyribonucleic acid (cDNA) have led to gene therapy trials on both sides of the Atlantic. However, gene therapy as a treatment for CF has yet to be realized.

Pharmacological manipulation of the biochemical defect may provide an alternative or complementary approach to treatment. This review will discuss pharmacological agents in development which could correct the abnormal ion movement.

The mechanisms of action of these pharmacological agents can be divided broadly into drugs which affect the most common CF mutation, F508, which increase trafficking of the mutant CF protein to the apical membrane; drugs which increase chloride secretion; and drugs which reduce sodium reabsorption across the apical membrane.

Treatment options for cystic fibrosis have developed rapidly since discovery of the cystic fibrosis gene over a decade ago. The targeting of specific therapies for particular cystic fibrosis genotypes and the use of combination treatments of chloride channel openers with sodium channel blockers are likely to be key advances in the next decade.

This article has been cited by other articles:

				S. Rajamani, C. L. Anderson, B. D. Anson, and C. T. January Pharmacological Rescue of Human K+ Channel Long-QT2 Mutations: Human Ether-a-Go-Go-Related Gene Rescue Without Block Circulation, June 18, 2002; 105(24): 2830 - 2835. [Abstract] [Full Text] [PDF]